Profound statement in pix.
Thanx for posting this eye opener
The following posts are shamelessly stolen from Treeper “Bob,” who has provided many posts I have posted here that many of you have found vetty interdasting.
________________________________
Part 1 of 3
Starting with the realization that Moderna required time, money and effort to develop the mRNA product based on someone elses patents long before there was even a proven market for COVID-19 vaccine. One of the two critical patent claims was filed on March 5, 2018, and the other on January 9, 2019. As you will see, these patents belonged to Arbutus Biopharma Corporation.
How did Moderna know, that it needed a COVID-19 vaccine almost 2 years before it was needed?
Moderna has filed several inter parties reviews (IPRs), including against:
Arbutus Biopharma Corporation’s (Arbutus) U.S. Patent No. 9,404,127 (IPR2018-00680 filed February 21, 2018: all claims found unpatentable),
Arbutus’ U.S. Patent No. 9,364,435 (IPR2018-00739 filed March 5, 2018: claims 1-6, 9, 12, 14, and 15 found unpatentable),
Arbutus’ U.S Patent No. 8,058,069 (IPR2019-00554 filed January 9, 2019: no challenged claims found unpatentable),
Moderna has also filed oppositions in the European Patent Office (EPO), including against Arbutus’ EP2279254 (Opposition filed April 2018: amended claims corresponding to Auxiliary Request 1 accepted and revocation denied, pending appeal by Moderna.
__________________________
Part 2 of 3
Moderna Wants Fed. Cir. Help to Avoid Covid Vaccine Patent Suits
Oct. 6, 2021, 4:00 AM
Moderna Inc. subsidiary ModernaTX will ask the Federal Circuit at oral arguments Thursday to invalidate two patents it says could make its Covid-19 vaccine vulnerable to infringement suits.
The Patent Trial and Appeals Board upheld parts of Arbutus Biopharma Corp.’s U.S. Patent Nos. 9,364,435 and 8,058,069, on drug-delivery technology. Arbutus argues Moderna has no standing to appeal those decisions because Moderna hasn’t suffered any injury related to the patents.
While the CAFC said that Moderna succeeded in proving that it has a “substantial risk that Arbutus will assert the ’069 patent in an infringement suit targeting Moderna’s COVID-19 vaccine,” and thus had standing to appeal, the court ultimately said that Moderna’s obviousness theory was “an oversimplification based on unfounded assumptions.”
________________________________
Moderna Strikes Out at CAFC on Challenges to Arbutus Patents that May Pose a Risk to COVID Vaccines
By IPWatchdog
December 2, 2021
“Moderna falls short of its burden to demonstrate that at the time it filed this appeal, it had suffered or was suffering a ‘concrete’ injury from the existence of the ’435 patent.” – CAFC
___________________________
Note: DARPA is a Bioweapon developer for the U.S. Government!! What does the Vaccine contain, that is a Bioweapon, after all look at the money DARPA provided? Could it be COVID-19?
Moderna failed to disclose federal funding for vaccine patent applications, advocates say
By Ed Silverman Aug. 28, 2020
One particular patent assigned to Moderna concerns methods and compositions that can be used specifically against coronaviruses, including COVID-19. The patent names a Moderna scientist and a former Moderna scientist as inventors, both of which acknowledged performing work under the DARPA awards in two academic papers, according to the report by the advocacy group.
The group examined the 126 patents assigned to Moderna or ModernaTx as well as 154 patent applications. “Despite the evidence that multiple inventions were conceived in the course of research supported by the DARPA awards, not a single one of the patents or applications assigned to Moderna disclose U.S. federal government funding,” the report stated.
[UPDATE: A DARPA spokesman sent us this over the weekend: “It appears that all past and present DARPA awards to Moderna include the requirement to report the role of government funding for related inventions. Further, DARPA is actively researching agency awards to Moderna to identify which patents and pending patents, if any at all, may be associated with DARPA support. This effort is ongoing.”]
We asked Moderna for comment and will update you accordingly.
The missive to the Department of Defense follows a recent analysis by Public Citizen, another advocacy group, indicating the National Institutes of Health may own mRNA-1273, the Moderna vaccine candidate for Covid-19. The advocacy group noted the federal government filed multiple patents covering the vaccine and two patent applications, in particular, list federal scientists as co-inventors.
As for the Moderna vaccine, earlier this month, the company was awarded a $1.525 billion contract by the Department of Defense and the Department of Health and Human Services to manufacture and deliver 100 million doses of its Covid-19 vaccine. The agreement also includes an option to purchase another 400 million doses, although the terms were not disclosed.
https://www.statnews.com/pharmalot/2020/08/28/moderna-covid19-vaccine-coronavirus-patents-darpa/
____________________________
Without the two patents referenced below and made by Arbutus would the mRNA product even exist? And without the mRNA would the COVID-19 vaccine (light) even exist? Thereby making the patents filed by the government worthless.
***************************************
The missive to the Department of Defense follows a recent analysis by Public Citizen, another advocacy group, indicating the National Institutes of Health may own mRNA-1273, the Moderna vaccine candidate for Covid-19. The advocacy group noted the federal government filed multiple patents covering the vaccine and two patent applications, in particular, list federal scientists as co-inventors.
https://www.statnews.com/pharmalot/2020/08/28/moderna-covid19-vaccine-coronavirus-patents-darpa/
*****************************************************************
Starting with the realization that Moderna required time, money and effort to develop the mRNA product based on someone elses patents long before there was even a proven market for COVID-19 vaccine. One of the two critical patent claims was filed on March 5, 2018, and the other on January 9, 2019. As you will see, these patents belonged to Arbutus Biopharma Corporation.
How did Moderna know, that it needed a COVID-19 vaccine almost 2 years before it was needed?
Moderna has filed several inter parties reviews (IPRs), including against:
Arbutus Biopharma Corporation’s (Arbutus) U.S. Patent No. 9,404,127 (IPR2018-00680 filed February 21, 2018: all claims found unpatentable),
Arbutus’ U.S. Patent No. 9,364,435 (IPR2018-00739 filed March 5, 2018: claims 1-6, 9, 12, 14, and 15 found unpatentable),
Arbutus’ U.S Patent No. 8,058,069 (IPR2019-00554 filed January 9, 2019: no challenged claims found unpatentable),
Moderna has also filed oppositions in the European Patent Office (EPO), including against Arbutus’ EP2279254 (Opposition filed April 2018: amended claims corresponding to Auxiliary Request 1 accepted and revocation denied, pending appeal by Moderna.
__________________________
Note: If you want to thank Bob, here is the link to the last post here.
You don’t need an account on CT to post; you just need to a username and email
You are most welQome!